<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1612246427
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KAPRON 500 mg/5ml Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TRANEXAMIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        26.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" Amoun Pharmaceutical Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             Amoun Pharmaceutical Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 467]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Thimar Aljazirah Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                             Amoun Pharmaceutical Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02AA02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">kapron&reg; is used in adults and children above one year of age for the prevention and treatment of bleeding due to a process that inhibits blood clotting called fibrinolysis.</p><p dir="ltr">Specific indications include:<br />- Heavy periods in women<br />- Gastrointestinal bleeding<br />- Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract.<br />- Ear, nose or throat surgery<br />&bull; heart, abdominal or gynaecological surgery<br />&bull; bleeding after you have been treated with another medicine to break down blood clots.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take kapron&reg;:</strong><br />&bull; If you are allergic to tranexamic acid or any of the other ingredients of this medicine (listed in section 6).<br />&bull; If you have currently a disease leading to blood clots.<br />&bull; If you have a condition called consumption coagulopathy where blood in the whole body starts to clots.<br />&bull; If you have kidney problems.<br />&bull; If you have a history of convulsions<br />Due to the risk of cerebral oedema and convulsions, intrathecal and intraventricular injection and intracerebral application are not recommended.<br />If you think, any of these apply to you, or if you are in any doubt at all, tell your doctor before taking kapron&reg;.</p><p dir="ltr"><br /><strong>Warnings and precautions</strong><br />Talk to your doctor or nurse if any of these apply to you to help him or her decide if kapron&reg; is suitable for you:<br />&bull; If you have had blood in your urine, it may lead to urinary tract obstruction.<br />&bull; If you have a risk of having blood clots.<br />&bull; If you have excessive clotting or bleeding throughout your body(disseminated intravascular coagulation), kapron&reg; may not be right for you, except if you have acute severe bleeding and blood tests have shown the process that inhibits blood clotting called fibrinolysis is activated.<br />&bull; If you have had convulsions, kapron&reg; should not be administered. Your doctor must use the minimal dose possible to avoid convulsions following treatment with kapron&reg;.<br />&bull; If you are on a long-term treatment with kapron&reg; Solution for Injection, attention should be paid to possible disturbances of colour vision and if<br />necessary the treatment should be discontinued. With continuous long-term use of kapron&reg;, regular ophthalmologic examinations (eye examinations<br />including visual acuity, colour vision, fundus, visual field etc.) are indicated. With pathological ophthalmic changes, particularly with diseases of the retina, your doctor must take a decision after consulting a specialist on the necessity for the long-term use of kapron&reg; in your case.</p><p dir="ltr"><strong>Other medicines and kapron&reg;</strong><br />Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines.<br />You should specifically tell them if you take:<br />&bull; other medicines that help blood to clot called antifibrinolytic medicines.<br />&bull; medicines that prevent blood clotting, called thrombolytic medicines.<br />&bull; oral contraceptives.</p><p dir="ltr"><br /><strong>Pregnancy, breast-feeding and fertility</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before<br />taking this medicine. Tranexamic acid is excreted in human milk. Therefore, the use of kapron&reg; during breast-feeding is not recommended.</p><p dir="ltr"><br /><strong>Driving and using machines</strong><br />No studies have been performed on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">kapron&reg; solution for injection will be given to you by slow injection into a vein.<br />Your doctor will decide the correct dose for you and how long you should take it.</p><p dir="ltr"><strong>Use in children</strong></p><p dir="ltr">If kapron&reg; solution for injection is given to a child from one year, the dose will be based on the child&rsquo;s weight.<br />Your doctor will decide the correct dose for the child and how long he/she should take it.<br /><strong>Use in elderly</strong><br />No reduction in dosage is necessary unless there is evidence of renal failure.<br /><strong>Use in patients with kidney problem</strong><br />If you have a kidney problem, your dose of tranexamic acid will be reduced<br />according to a test performed on your blood (serum creatinine level).<br /><strong>Use in patients with hepatic impairment</strong><br />No reduction in dosage is necessary.<br /><strong>Method of administration</strong><br />kapron&reg; should only be administered slowly into a vein.<br />kapron&reg; must not be injected into a muscle.<br /><strong>If you are given more kapron&reg; than the recommended dose</strong><br />If you are given more kapron&reg; than the recommended dose you may experience a transitory blood pressure lowering. Talk to a doctor or pharmacist immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Side effects reported with kapron&reg; are:<br />The following side effects have been observed with kapron&reg;<br /><strong>Common:</strong> may affect up to 1 in 10 people<br />&bull; effects on the stomach and intestines: nausea, vomiting, diarrhoea<br /><strong>Uncommon:</strong> may affect up to 1 in 100 people<br />&bull; effects on the skin problems: rash<br /><strong>Not known:</strong> frequency cannot be estimated from the available data<br />&bull; malaise with hypotension (low blood pressure), especially if the injection is given too quickly<br />&bull; blood clots<br />&bull; effects on the nervous system: convulsions<br />&bull; effects on the eyes: vision disturbances including impaired colour vision<br />&bull; effects on the immune system: allergic reactions</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton and ampoule label after EXP. The expiry date refers to the last day of that month.<br />Do not freeze.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What kapron&reg; contains</strong><br />The active substance is tranexamic acid.<br />Each 5 ml of the solution contains 500 mg of tranexamic acid.<br />The other ingredient is water for injections.<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
kapron® containing six transparent ampoules of type I glass each of 5 ml clear colorless solution
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorization Holder and Manufacturer</strong><br />Amoun Pharmaceutical Company<br />1st industrial Zone, El obour city, Cairo, Egypt<br />Tel: (202) 46140100 (10 lines)<br />Fax: (202)46103500<br />Email: export@amoun.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;ينتمى كابرون<strong><sup>&reg;</sup></strong> لمجموعة من الادوية تسمى مضادات النزيف &nbsp;و مضادات عامل تحلل الفيبرين واحماض امينية . يستخدم كابرون<strong><sup>&reg;</sup></strong> &nbsp;في الأطفال من سن أكبر من&nbsp; سنة&nbsp; والبالغين &nbsp;للوقاية ولعلاج &nbsp;النزيف نتيجة لحدوث خطوات التي تمنع تجلط الدم تسمى تحلل الفيبرين .</p><p dir="RTL">&nbsp; &nbsp;استخدامات خاصة وتشمل :</p><ul dir="rtl"><li>&nbsp; &nbsp; نزيف الطمث الشديد</li><li>&nbsp; &nbsp;نزيف الجهاز الهضمي</li><li>&nbsp; النزيف الناتج عن امراض الجهاز البولي, بعد عمليات البروستاتة أو بعد عمليات المسالك البولية</li><li>&nbsp; عمليات الأنف والأذن والحلق &nbsp;</li><li>&nbsp; عمليات القلب والبطن أو عمليات الجهاز التناسلي الأنثوي</li><li>&nbsp; النزيف الذى يحدث بعد استعمالك لأدوية مضادات التجلط</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لاتستخدم كابرون</strong><strong><sup>&reg; </sup></strong><strong>&nbsp;إذا :-</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية لمادة حمض ترانكسيمك أو أي من المواد الغير فعالة في هذا الدواء .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان كنت تعانى من مرض يؤدى لحدوث الجلطات الدموية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدث لك أعراض&nbsp; تسمى&nbsp; استهلاك عوامل التجلط المرضى .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تعانى من مشاكل&nbsp; بالكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ مرضى من التشنجات</p><p dir="RTL">نتيجة لوجود احتمالية حدوث تورم بالمخ أو تشنجات , لا يوصى بأعطاء &nbsp;<strong>كابرون</strong><strong><sup>&reg;&nbsp;&nbsp; &nbsp;</sup></strong>بالحقن بالنخاع الشوكى أو داخل غرف &nbsp;المخ &nbsp;.</p><p dir="RTL">إذا كنت تعتقد ان لديك أي من الأمراض السابقة &nbsp;, أذا كان لديك أي من الشكوك على الأطلاق, &nbsp;أخبر طبيبك قبل أخذ <strong>كابرون</strong><strong><sup>&reg;</sup></strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات و التحذيرات &nbsp;:</strong></p><p dir="RTL">أخبر طبيبك أو الممرضة &nbsp;إذا حدث اى من هذة الاعراض لك ليقرر إذا كان حقن كابرون<strong><sup>&reg;</sup></strong> مناسبة لك :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك دم بالبول ,قد يؤدى لحدوث انسداد بالمجاري البولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كان لديك خطر الأصابة بتجلطات بالدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كان لديك تجلطات أو نزيف بالجسم زائد منتشر بالجسم (تخثر الدم داخل الاوعية) , قد يكون<strong> كابرون</strong><strong><sup>&reg;&nbsp;&nbsp; </sup></strong>غير مناسب لك ألا اذا كان لديك<strong><sup> </sup></strong>&nbsp;نزيف حاد وفحوصات الدم أوضحت ان لديك العوامل التي&nbsp; تمنع تجلط الدم تسمى زيادة &nbsp;عامل تحلل الفيبرين&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تشنجات , لا يجب &nbsp;أعطاء&nbsp; <strong>كابرون</strong><strong><sup>&reg;&nbsp; &nbsp;</sup></strong>&nbsp;يجب ان يقوم طبيبك بتقليل الجرعة لتقليل احتمالية حدوث تشنجات بعد العلاج باستخدام <strong>كابرون</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أذا كنت&nbsp;&nbsp; على علاج لفترة طويلة باستخدام <strong>كابرون</strong><strong><sup>&reg; </sup></strong>محلول للحقن</p><p dir="RTL">يجب إعطاء الانتباه لحدوث مشاكل في رؤية الألوان&nbsp; ويكون من الضروري إيقاف الدواء&nbsp; . مع العلاج المستمر باستخدام <strong>كابرون</strong><strong><sup>&reg; </sup></strong>&nbsp;&nbsp;يجب عمل فحص للعينين ( فحص العينين شاملا حدة الأبصار , رؤية الألوان و مجال الرؤية ..الخ ) . يجب ان يتخذ طبيبك القرار بعد العرض على استشاري الرمد عن ضرورة استخدام <strong>كابرون</strong><strong><sup>&reg;</sup></strong>على المدى الطويل في مريضك . &nbsp;&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الأدوية الأخرى و كابرون</strong> <strong><sup>&reg;</sup></strong><strong>:</strong></p><p dir="RTL">&nbsp; يجب اخبار طبيبك أو الممرضة أو الصيدلي إذا كنت تتناول حديثا أو تتناول أى من الادوية الأخرى .</p><p dir="RTL">يجب ان تخبر طبيبك اذا كنت تتناول بصفة خاصة :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ادوية أخرى التي تساعد الدم ان يتجلط تدعى مضادات عامل تحلل الفيبرين .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تمنع التجلط تسمى مضادات التخصر .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص منع الحمل التي تعطى عن طريق الفم .</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحمل والرضاعة الطبيعية : -</strong></p><p dir="RTL">إذا كنت حاملاً او ترضعين طفلك أو تفكرين في الحمل أو تخططين لولادة طفلك اطلب من طبيبك &nbsp;أو الصيدلي النصيحة قبل تناول كابرون<strong><sup>&reg;</sup></strong> . يفرز&nbsp; حمض ترانيكسامك في لبن الأم . لذلك لا يوصى باستخدام كابرون<strong><sup>&reg; </sup></strong>اثناء الرضاعة<strong><sup> .</sup></strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>القيادة واستخدام الألات:-</strong></p><p dir="RTL">لم يتم عمل&nbsp; أي دراسات حول القدرة على&nbsp; قيادة السيارة او تشغيل ألآلات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عادة يتم حقن كابرون<strong><sup>&reg;</sup></strong> ببطء فى الوريد. سوف يقرر طبيبك &nbsp;الجرعة الصحيحة لك والمدة التي تحتاجها لتناول الدواء .</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp;الاستعمال في الأطفال :</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>أذا تم أعطاء <strong>كابرون</strong><strong><sup>&reg;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup></strong>محلول للحقن للأطفال ,سوف يتم أعطاء الجرعة حسب وزن الطفل . سوف يقرر الجرعة الصحيحة للطفل والمدة التي يحتاجها أو تحتاجها .&nbsp;&nbsp; <strong><sup>&nbsp;&nbsp;</sup></strong></p><p dir="RTL"><strong>كبار السن</strong> :-</p><p dir="RTL">لا يوجد تقليل للجرعة الا اذا كان المريض يعانى من فشل كلوى .</p><p dir="RTL"><strong>الاستعمال في المرضى الذين يعانون من مشاكل بالكلى </strong></p><p dir="RTL">اذا كان لديك مشاكل بالكلى , سوف يتم خفض جرعة&nbsp; حمض الترانكسمك حسب تحليل يتم عملة على دم المريض ( مستوى الكرياتينين&nbsp; بالبلازما )</p><p dir="RTL"><strong>الاستعمال في المرضى الذين يعانون من مشاكل بالكبد</strong></p><p dir="RTL">خفض الجرعة غير ضروري</p><p dir="RTL">&nbsp;&nbsp;<strong>طريقة</strong> <strong>الاستعمال </strong></p><p dir="RTL">يعطى<strong> كابرون</strong><strong><sup>&reg;</sup></strong><strong> </strong>فقط عن طريق الحقن الوريدى ببطء</p><p dir="RTL">يجب عدم أعطاء <strong>كابرون</strong><strong><sup>&reg;</sup></strong> عن طريق الحقن بالعضل</p><p dir="RTL"><strong>اذا تم إعطاء جرعة زائدة من كابرون</strong><strong><sup>&reg;</sup></strong><strong>&nbsp;&nbsp;&nbsp; اكثر من الجرعة المحددة</strong></p><p dir="RTL">اذا تم إعطاء جرعة زائدة من<strong> كابرون</strong><strong><sup>&reg;</sup></strong><strong>&nbsp;&nbsp;&nbsp; </strong>اكثر من الجرعة المحددة لك قد يحدث لك هبوط عابر في ضغط الدم . تكلم مع طبيبك أو الصيدلي في الحال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل بقية الأدوية قد يسبب هذا الدواء &nbsp;بعض الاعراض الجانبية ولكن ليس لكل المرضى</p><p dir="RTL"><strong>الاثار الجانبية المسجلة مع </strong></p><p dir="RTL">لوحظت بعض من هذة الاعراض الجانبية مع العلاج بال<strong>كابرون</strong><strong><sup>&reg;</sup></strong> مثل :-</p><p dir="RTL">شائعة : قد تؤثر على 1 من كل 10 مرضى</p><p dir="RTL">تأثيره على المعدة والأمعاء : غثيان , قيء ,اسهال</p><p dir="RTL">غير شائعة : قد تؤثر على 1 من كل 100 مرضى&nbsp;</p><p dir="RTL">تأثيره على مشاكل الجلد :طفح جلدى</p><p dir="RTL">غير معروف : معدلات حدوثة لا يمكن حسابها من المعلومات المتوفرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأعياء من ضغط الدم المنخفض &nbsp;(انخفاض ضغط الدم) ,خصوصا اذا تم الحقن بسرعة جدا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيره على الجهاز العصبي : تشنجات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيره على العيون : إضرابات الرؤية شاملا انخفاض رؤية الألوان .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيره على الجهاز المناعي : تفاعل الحساسي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يحفظ هذا الدواء&nbsp; بعيد عن نظر ومتناول الاطفال.</strong></p><p dir="RTL">لا يجب استخدام حقن كابرون<strong><sup>&reg;</sup></strong> بعد تاريخ إنتهاء الصلاحية المطبوع على العلبة وسوف يفحص الصيدلى هذا التاريخ قبل إعطاءك الحقن .</p><p dir="RTL">لا تجمد الأمبولات</p><p dir="RTL">لا يجب التخلص من أي ادوية عن طريق الصرف الصحي أو القائها في القمامة .</p><p dir="RTL">هذه الوسائل سوف تحافظ على البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كابرون<strong><sup>&reg;</sup></strong> حقن عبارة عن محلول يحتوى على 500 مجم حمض ترانكسيمك فى 5 مل</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;العبوات: - علبة تحتوى على 6 أمبولات شفافة بها محلول صافي شفاف.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة امون للأدوية</p><p dir="RTL">المنطقة الصناعية الاولي، مدينة العبور، القاهرة، مصر</p><p dir="RTL">هاتف: (202) 46140100 (10 خطوط)</p><p dir="RTL">&nbsp; فاكس: (202) 46103500</p><p dir="RTL">البريد الإلكتروني: export@amoun.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Kapron Ampoule
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 ml Ampoule contains Tranexamic acid 500 mg
Excipients: Water for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clear Colourless solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention and treatment of haemorrhages due to general or local fibrinolysis in adults and children from one year.<br />Specific indications include:<br />- Haemorrhage caused by general or local fibrinolysis such as:<br />- Menorrhagia and metrorrhagia,<br />- Gastrointestinal bleeding,<br />- Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract,<br />- Ear Nose Throat surgery (adenoidectomy, tonsillectomy, dental extractions),<br />- Gynaecological surgery or disorders of obstetric origin,<br />- Thoracic and abdominal surgery and other major surgical intervention such as cardiovascular surgery,<br />- Management of haemorrhage due to the administration of a fibrinolytic agent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Posology</strong></u><br /><strong>Adults</strong><br />Unless otherwise prescribed, the following doses are recommended:<br />1. Standard treatment of local fibrinolysis:<br />0.5 g (1 ampoule of 5 mL) to 1 g (1 ampoule of 10 mL or 2 ampoules of 5 mL) tranexamic acid by slow intravenous injection (= 1 mL/minute) two to three times daily<br />2. Standard treatment of general fibrinolysis:<br />1 g (1 ampoule of 10 mL or 2 ampoules of 5 mL) tranexamic acid by slow intravenous injection (= 1 mL/minute) every 6 to 8 hours, equivalent to 15 mg/kg BW.<br /><strong>Renal impairment</strong><br />In renal insufficiency leading to a risk of accumulation, the use of tranexamic acid is contraindicated in patients with severe renal impairment . For patients with mild to moderate renal impairment, the dosage of tranexamic acid should be reduced according to the serum creatinine level:</p><p><br /><img alt="" width="600" height="112" src="data:image/png;base64,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" /><br />&nbsp;</p><p><strong>Hepatic impairment</strong><br />No dose adjustment is required in patients with hepatic impairment.<br />Paediatric Population<br />In children from 1 year, for current approved indications,&nbsp;the dosage is in the region of 20 mg/kg/day. However, data on efficacy, posology and safety for these indications are limited.<br />The efficacy, posology and safety of tranexamic acid in children undergoing cardiac surgery have not been fully established.&nbsp;</p><p><br /><strong>Elderly</strong><br />No reduction in dosage is necessary unless there is evidence of renal failure.<br />&nbsp;</p><p><strong>Method of administration</strong><br />The administration is strictly limited to slow intravenous injection.<br />.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients .
Acute venous or arterial thrombosis .
Fibrinolytic conditions following consumption coagulopathy except in those with predominant activation of the fibrinolytic system with acute severe bleeding .
Severe renal impairment (risk of accumulation)
History of convulsions
Intrathecal and intraventricular injection, intracerebral application (risk of cerebral oedema and convulsions)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The indications and method of administration indicated above should be followed strictly:</p><p>&bull; Intravenous injections should be given very slowly.<br />&bull; Tranexamic acid should not be administered by the intramuscular route.</p><p><strong><u>Convulsions</u></strong></p><p>Cases of convulsions have been reported in association with tranexamic acid treatment. In coronary artery bypass graft (CABG) surgery, most of these cases were reported following intravenous (i.v.) injection of tranexamic acid in high doses. With the use of the recommended lower doses of tranexamic acid, the incidence of post-operative seizures was the same as that in untreated patients.</p><p><u><strong>Visual disturbances</strong></u><br />Attention should be paid to possible visual disturbances including visual impairment, vision blurred, impaired colour vision and if necessary the treatment should be discontinued. With continuous long-term use of tranexamic acid solution for injection, regular ophthalmologic examinations (eye examinations including visual acuity, colour vision, fundus, visual field etc.) are indicated. With pathological ophthalmic changes, particularly with diseases of the retina, the physician must decide after consulting a specialist on the necessity for the long-term use of tranexamic acid solution for injection in each individual case.</p><p><u><strong>Haematuria</strong></u><br />In case of haematuria from the upper urinary tract, there is a risk for urethral obstruction.</p><p><u><strong>Thromboembolic events</strong></u><br />Before use of tranexamic acid, risk factors of thromboembolic disease should be considered. In patients with a history of thromboembolic diseases or in those with increased incidence of thromboembolic events in their family history (patients with a high risk of thrombophilia), Tranexamic acid solution for injection should only be administered if there is a strong medical indication after consulting a physician experienced in hemostaseology and under strict medical supervision .<br />Tranexamic acid should be administered with care in patients receiving oral contraceptives because of the increased risk of thrombosis .</p><p><u><strong>Disseminated intravascular coagulation</strong></u><br />Patients with disseminated intravascular coagulation (DIC) should in most cases not be treated with tranexamic acid . If tranexamic acid is given it must be restricted to those in whom there is predominant activation of the fibrinolytic system with acute severe bleeding. Characteristically, the haematological profile approximates to the following: reduced euglobulin clot lysis time; prolonged prothrombin time; reduced plasma levels of fibrinogen, factors V and VIII, plasminogen fibrinolysin and alpha-2 macroglobulin; normal plasma levels of P and P complex; i.e. factors II (prothrombin), VIII and X; increased plasma levels of fibrinogen degradation products; a normal platelet count. The foregoing presumes that the underlying disease state does not of itself modify the various elements in this profile. In such acute cases a single dose of 1 g tranexamic acid is frequently sufficient to control bleeding. Administration of tranexamic acid in DIC should be considered only when appropriate haematological laboratory facilities and expertise are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. Simultaneous treatment with anticoagulants must take place under the strict supervision of a physician experienced in this field. Medicinal products that act on haemostasis should be given with caution to patients treated with tranexamic acid. There is a theoretical risk of increased thrombus-formation potential, such as with oestrogens. Alternatively, the antifibrinolytic action of the drug may be antagonised with thrombolytic drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential have to use effective contraception during treatment.</p><p><u><strong>Pregnancy</strong></u></p><p>There are no or limited amount of data from the use of tranexamic acid in pregnant women. As a result, although studies in animals do not indicate teratogenic effects, as precaution for use, tranexamic acid is not recommended during the first trimester of pregnancy.<br />Limited clinical data of the use of tranexamic acid in different clinical haemorrhagic settings during the second and third trimesters did not identify deleterious effect for the foetus. Tranexamic acid should be used throughout pregnancy only if the expected benefit justifies the potential risk.</p><p><u><strong>Breast-feeding</strong></u></p><p>Tranexamic acid is excreted in human milk. Therefore, breast-feeding is not recommended.</p><p><u><strong>Fertility</strong></u></p><p>There are no clinical data on the effects of tranexamic acid on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been performed on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ADRs reported from clinical studies and post-marketing experience are listed below according to system organ class.</p><p><u><strong>Tabulated list of adverse reactions</strong></u></p><p>Adverse reactions reported are presented in table below. Adverse reactions are listed according to MedDRA primary system organ class. Within each system organ class, adverse reactions are ranked by frequency. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><table border="1" cellspacing="1" cellpadding="1" style="width:688px"><tbody><tr><td style="text-align:center; width:224px"><strong>System organ class</strong></td><td style="text-align:center; width:93px"><strong>Common<br />&ge; 1/100 to &lt; 1/10</strong></td><td style="text-align:center; width:109px"><strong>Uncommon<br />&ge; 1/1,000 to &lt; 1/100</strong></td><td style="text-align:center; width:259px"><strong>Frequency not known<br />(cannot be estimated from the available data)</strong></td></tr><tr><td style="width:224px">Immune system disorders</td><td style="width:93px">&nbsp;</td><td style="width:109px">&nbsp;</td><td style="width:259px">- Hypersensitivity reactions including anaphylaxis</td></tr><tr><td style="width:224px">Nervous system disorders</td><td style="width:93px">&nbsp;</td><td style="width:109px">&nbsp;</td><td style="width:259px">- Convulsions particularly in case of misuse (refer to sections 4.3 and 4.4)</td></tr><tr><td style="width:224px">Eye disorder&nbsp;</td><td style="width:93px">&nbsp;</td><td style="width:109px">&nbsp;</td><td style="width:259px">- Visual disturbances including impaired colour vision</td></tr><tr><td style="width:224px">Vascular disorder&nbsp;</td><td style="width:93px">&nbsp;</td><td style="width:109px">&nbsp;</td><td style="width:259px">Malaise with hypotension, with or without loss of consciousness (generally&nbsp;following a too fast intravenous injection, exceptionally after oral administration)<br />- Arterial or venous thrombosis at any sites</td></tr><tr><td style="width:224px">Gastrointestinal disorder&nbsp;</td><td style="width:93px">-Diarrhoea<br />- Vomiting<br />- Nausea</td><td style="width:109px">&nbsp;</td><td style="width:259px">&nbsp;</td></tr><tr><td style="width:224px">Skin and subcutaneous tissue disorders</td><td style="width:93px">&nbsp;</td><td style="width:109px">Dermatitis allergic</td><td style="width:259px">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions </strong></p><p><strong>Reporting of suspected adverse reactions after authorisation of the medicinal product is important</strong>. It allows continued monitoring of the benefit/risk balance of the medicinal product.<br />To report any side effects:</p><p><strong> Saudi Arabia:</strong><br /><u>The National Pharmacovigilance and drug Safety center (NPC)</u></p><ul><li> Fax: +966-11-205-7662</li><li> Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340</li><li> Toll free phone: 8002490000</li><li> Email: npc.drug@fda.gov.sa</li><li> Website: www.sfda.gov.sa/npc</li></ul><p><strong> Other GCC states:</strong></p><ul><li>Please contact the relevant competent authority</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported.<br />Signs and symptoms may include dizziness, headache, hypotension, and convulsions. It has been shown that convulsions tend to occur at higher frequency with increasing dose.<br />Management of overdose should be supportive.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antihaemorrhagics, Antifibrinolytics, Aminoacids<br />ATC code: B02AA02<br />Tranexamic acid exerts an anti haemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.<br />A complex involving tranexamic acid, plasminogen is constituted; the tranexamic acid being linked to plasminogen when transformed into plasmin.&nbsp; &nbsp;</p><p>The activity of the tranexamic acid-plasmin complex on the activity on fibrin is lower than the activity of free plasmin alone.<br />In vitro studies showed that high tranexamic dosages decreased the activity of complement.</p><p><u>Paediatric population</u></p><p>In children over one year old</p><p>Literature review identified 12 efficacy studies in paediatric cardiac surgery which have included 1073 children, 631 having received tranexamic acid. Most of them were controlled versus placebo. Studied population was heterogenic in terms of age, surgery types, dosing schedules. Study results with tranexamic acid suggest reduced blood loss and reduced blood product requirements in paediatric cardiac surgery under cardiopulmonary bypass (CPB) where there is a high risk of haemorrhage, especially in cyanotic patients or patients undergoing repeat surgery.The most adapted dosing schedule appeared to be:</p><p>- first bolus of 10 mg/kg after induction of anaesthesia and prior to skin incision,<br />- continuous infusion of 10 mg/kg/h or injection into the CPB pump prime at a dose adapted on the CPB procedure, either according to a patient weight with a dose of 10 mg/kg dose, either according to CPB pump prime volume, last injection of 10 mg/kg at the end of CPB.<br />While studied in very few patients, the limited data suggest that continuous infusion is preferable, since it would maintain therapeutic plasma concentration throughout surgery.</p><p>No specific dose-effect study or PK study has been conducted in children.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Peak plasma concentrations of tranexamic acid are obtained rapidly after a short intravenous infusion after which plasma concentrations decline in a multi-exponential manner.</p><p>&nbsp;</p><p><strong>Distribution</strong></p><p>The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen. Tranexamic acid does not bind to serum albumin. The initial volume of distribution is about 9 to 12 litres.<br />Tranexamic acid passes through the placenta. Following administration of an intravenous injection of 10 mg/kg to 12 pregnant women, the concentration of tranexamic acid in serum ranged 10-53 &mu;g/mL while that in cord blood ranged 4-31 &mu;g/mL. Tranexamic acid diffuses rapidly into joint fluid and the synovial membrane. Following administration of an intravenous injection of 10 mg/kg to 17 patients undergoing knee surgery, concentrations in the joint fluids were similar to those seen in corresponding serum samples. The concentration of tranexamic acid in a number of other tissues is a fraction of that observed in the blood (breast milk, one hundredth; cerebrospinal fluid, one tenth; aqueous humor, one tenth). Tranexamic acid has been detected in semen where it inhibits fibrinolytic activity but does not influence sperm migration.</p><p><br /><strong>Elimination</strong></p><p>It is excreted mainly in the urine as unchanged drug. Urinary excretion via glomerular filtration is the main route of elimination. Renal clearance is equal to plasma clearance (110 to 116 mL/min). Excretion of tranexamic acid is about 90% within the first 24 hours after intravenous administration of 10 mg/kg body weight. Elimination half-life of tranexamic acid is approximately 3 hours.</p><p>&nbsp;</p><p><strong>Special populations</strong></p><p>Plasma concentrations increase in patients with renal failure.<br />No specific PK study has been conducted in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Epileptogenic activity has been observed in animals with intrathecal use of tranexamic acid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Kapron Ampoule contain the following excipient:<br />Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product should not mixed with blood for transfusion or with solutions containing penicillin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
After first opening: the solution for injection is for single use only. Unused solution for injection must be discarded.
Chemical and physical in-use stability has been demonstrated for 24 hours at 30°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Do not freeze.</li><li>For storage conditions after first opening of the medicinal product:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Chemical and physical in-use stability has been demonstrated for 24 hours at 30&deg;C.</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carton box contains 6 transparent Type I glass 5 ml ampoules with inner leaflet, each Ampoule contains 500 mg tranexamic acid</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Kapron for injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions and dextran solutions. Heparin may be added to Kapron injection.<br />Kapron for injection is for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amoun Pharmaceutical Company SAE
1st industrial zone, El-Obour city Cairo, Egypt
Tel: (202) 46140100 (10 lines)
Fax: (202)46103500
Email: export@amoun.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>